ABSTRACT
COVID-19 is an unforeseen pandemic engendered by novel SARS COV-II virus, which shattered the lives of people globally from 2019. Although several vaccines have been developed in recent past, the detailed study of the effect of the same is still on advancement. The miserable fact is that there is no complete medication against the virus;however, the palliative treatment is being given on the basis of associated symptoms like pneumonia, pulmonary fibrosis, ARDS, difficulty in breathing, and so on. Several antiviral, antimalarial drugs and antibiotics have been attempted to minimize the peril, but the use of these drugs could negatively affect the patients’ health. Scientists were eagerly looking for an alternative therapy to lessen the symptoms and started thinking of regenerative therapy with stem cells. As the therapy has a potential history of treating several pulmonary disorders, it was a possible aspiration toward the treatment of COVID-19. In this regard, several clinical trials were carried out using different types of stem cells, while in particular MSCs have been specialized in amending the cytokine storm occurred on account of the pandemic. Considering the fact that the regenerative therapy is a long-run process and there is way to go forward with it, more advanced therapies may proceed in the future to halt the adverse effect of COVID-19 pandemic. © 2022 Elsevier Inc. All rights reserved.